ZA202005388B - Methods of treating ulcerative colitis - Google Patents

Methods of treating ulcerative colitis

Info

Publication number
ZA202005388B
ZA202005388B ZA2020/05388A ZA202005388A ZA202005388B ZA 202005388 B ZA202005388 B ZA 202005388B ZA 2020/05388 A ZA2020/05388 A ZA 2020/05388A ZA 202005388 A ZA202005388 A ZA 202005388A ZA 202005388 B ZA202005388 B ZA 202005388B
Authority
ZA
South Africa
Prior art keywords
ulcerative colitis
methods
treating ulcerative
treatment
treating
Prior art date
Application number
ZA2020/05388A
Other languages
English (en)
Inventor
James Benedict Canavan
Stuart William Friedrich
Kathryn Ann Krueger
Catherine Milch
Jay Lawrence Tuttle
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA202005388B publication Critical patent/ZA202005388B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA2020/05388A 2018-03-30 2020-08-28 Methods of treating ulcerative colitis ZA202005388B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
ZA202005388B true ZA202005388B (en) 2025-05-28

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/05388A ZA202005388B (en) 2018-03-30 2020-08-28 Methods of treating ulcerative colitis

Country Status (29)

Country Link
US (2) US12152072B2 (enExample)
EP (2) EP4327866B1 (enExample)
JP (4) JP7119114B2 (enExample)
KR (1) KR102552693B1 (enExample)
CN (1) CN111936165A (enExample)
AU (2) AU2019243283C1 (enExample)
BR (1) BR112020018099A2 (enExample)
CA (1) CA3095297A1 (enExample)
DK (1) DK3773715T3 (enExample)
EA (1) EA202091989A1 (enExample)
ES (1) ES2983809T3 (enExample)
FI (1) FI3773715T3 (enExample)
HR (1) HRP20240904T1 (enExample)
HU (1) HUE067445T2 (enExample)
IL (2) IL277514B2 (enExample)
LT (1) LT3773715T (enExample)
MA (1) MA52216B1 (enExample)
MD (1) MD3773715T2 (enExample)
MX (1) MX2020010269A (enExample)
MY (1) MY202368A (enExample)
PL (1) PL3773715T3 (enExample)
PT (1) PT3773715T (enExample)
RS (1) RS65661B1 (enExample)
SG (1) SG11202009526RA (enExample)
SI (1) SI3773715T1 (enExample)
TW (2) TWI837532B (enExample)
UA (1) UA128578C2 (enExample)
WO (1) WO2019191464A1 (enExample)
ZA (1) ZA202005388B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
US20210253690A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
BR112023013444A2 (pt) * 2021-01-06 2024-01-23 Abbvie Deutschland Métodos para tratar doença de crohn e colite ulcerativa
KR20240012469A (ko) * 2021-05-20 2024-01-29 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
CA3219846A1 (en) * 2021-05-28 2022-12-01 Venkatesh Krishnan Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
EP4623001A1 (en) * 2022-11-22 2025-10-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
AU2024236477A1 (en) 2023-03-10 2025-09-11 Eli Lilly And Company Methods of treating ulcerative colitis
TW202500185A (zh) * 2023-06-16 2025-01-01 大陸商信達生物製藥(蘇州)有限公司 重組抗白介素23p19亞基抗體在治療炎症性腸病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3501537A1 (en) * 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗il−23抗体、組成物、方法および用途
BRPI0807710B1 (pt) 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
US20190269757A1 (en) * 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody

Also Published As

Publication number Publication date
JP2025020134A (ja) 2025-02-12
US12152072B2 (en) 2024-11-26
AU2019243283A1 (en) 2020-09-24
US20210032325A1 (en) 2021-02-04
JP7119114B2 (ja) 2022-08-16
AU2019243283B2 (en) 2023-07-27
IL277514B2 (en) 2024-11-01
US20250034243A1 (en) 2025-01-30
EP3773715A1 (en) 2021-02-17
HRP20240904T1 (hr) 2024-10-11
KR102552693B1 (ko) 2023-07-07
SG11202009526RA (en) 2020-10-29
EA202091989A1 (ru) 2021-01-13
JP2022169562A (ja) 2022-11-09
FI3773715T3 (fi) 2024-05-30
KR20200128101A (ko) 2020-11-11
MD3773715T2 (ro) 2024-10-31
IL312807B2 (en) 2025-06-01
JP2021517156A (ja) 2021-07-15
EP3773715B1 (en) 2024-05-08
TWI744617B (zh) 2021-11-01
EP4327866A3 (en) 2024-03-20
JP7331219B2 (ja) 2023-08-22
JP7571225B2 (ja) 2024-10-22
CN111936165A (zh) 2020-11-13
IL277514B1 (en) 2024-07-01
MX2020010269A (es) 2020-11-06
MY202368A (en) 2024-04-24
UA128578C2 (uk) 2024-08-21
HUE067445T2 (hu) 2024-10-28
AU2023248103A1 (en) 2023-11-09
PL3773715T3 (pl) 2024-08-19
IL277514A (en) 2020-11-30
PT3773715T (pt) 2024-05-27
NZ767902A (en) 2024-05-31
SI3773715T1 (sl) 2024-06-28
LT3773715T (lt) 2024-06-25
TW202206104A (zh) 2022-02-16
EP4327866A2 (en) 2024-02-28
EP4327866B1 (en) 2025-12-10
MA52216B1 (fr) 2024-07-31
IL312807B1 (en) 2025-02-01
RS65661B1 (sr) 2024-07-31
TW201946657A (zh) 2019-12-16
JP2023166388A (ja) 2023-11-21
ES2983809T3 (es) 2024-10-24
AU2019243283C1 (en) 2024-05-02
CA3095297A1 (en) 2019-10-03
DK3773715T3 (da) 2024-05-27
BR112020018099A2 (pt) 2020-12-22
MA52216A (fr) 2021-02-17
WO2019191464A1 (en) 2019-10-03
TWI837532B (zh) 2024-04-01
IL312807A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
ZA202005388B (en) Methods of treating ulcerative colitis
MA39906A (fr) Polythérapies pour le traitement du cancer
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MY190034A (en) Method of treating cancer associated with a ras mutation
MX2017010150A (es) Bacterias probioticas recombinantes.
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
PH12018501443A1 (en) Methods of administering hepcidin
SG10201804034QA (en) Methods for treating hypotension
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
MX388593B (es) Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2019004804A (es) Tratamiento para el prurigo nodula.
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer
MX382608B (es) Tratamiento del prurito urémico.
ZA202108094B (en) Mirikizumab for use in a method of treating crohn's disease
MX2019014291A (es) Metodo de tratamiento.